Gilead Sciences Inc
(BUE:GILD)
ARS
26600
125 (0.47%)
Market Cap: 111.51 Tn
Enterprise Value: 131.94 Tn
PE Ratio: 110.08
PB Ratio: 6.15
GF Score: 52/100 Gilead Sciences Inc at Bank of America Global Healthcare Conference Transcript
May 09, 2023 / 06:20PM GMT
Release Date Price:
ARS8893.5
(-0.96%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
(technical difficulty) to the morning session of the BofA Healthcare Conference. So my name is Geoff Meacham. I'm the senior biopharma analyst. And we're thrilled today to have Gilead Sciences. And up on stage with me is Andy Dickinson. Andy, welcome.
Andrew D. Dickinson
Gilead Sciences, Inc. - Executive VP & CFO
Thank you. Great to be here. Thanks for having us.
Questions & Answers
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
So Andy, let's kick off with just following first quarter. Give us some perspective on kind of the guidance changes that you guys have made with respect to R&D and kind of what implications that has as kind of the expenses over the course of the year.
Andrew D. Dickinson
Gilead Sciences, Inc. - Executive VP & CFO
Sure. Yes. Maybe I'll start actually just by hitting kind of on the top line first and then
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot